EUVIMEDEUVIMED entdecken
Crossref

Forecasting Asparaginase Need and Cost for Childhood Cancer Using ACCESS FORxECAST

Terence M Hughes iD, Nitin Shrivastava iD, Lewis B Silverman iD, A Lindsay Frazier iD, Sumit Gupta iD, Avram Denburg iD

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Terence M Hughes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Medicine Residency at the Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Asparaginase, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Asparaginase (ASN) is a critical component of pediatric ALL protocols. Until recently, ASN was available in three formulations: native Escherichia coli, PEGylated E. coli (PEG), and Erwinase, with native E. coli typically more accessible in low- and middle-income countries (LMICs). Short shelf lives, intermittent availability, and concern for substandard formulations in LMICs have created a need for proactive ASN demand estimates. METHODS We adapted FORxECAST, a pediatric cancer drug forecasting model, to focus on ASN for pediatric ALL. The model is adaptable to user data and defaults to best available public data where local data are unavailable. We forecast ASN quantity and cost in three case study countries for four scenarios using two regimens—base regimen (BR) and intensified regimen (IR)—outlining how quantity and costs vary on the basis of ASN formulation, dose, and second-line availability. RESULTS Native E. coli is cheaper than PEG for first-line treatment across all scenarios. Regimen intensification from BR to IR requires a substantially higher cost when PEG is used relative to native E. coli. The cost of treating ASN hypersensitivity with Erwinase for BR in Burundi, Ghana, and Turkmenistan is $19,660 in US dollars (USD), $24,800 USD, and $15,246 USD, respectively. CONCLUSION Treatment intensification requires a cost increase that should be accessible for most LMICs, but PEG utilization is substantially more costly, suggesting that prioritizing investment in intensifying treatment using native E. coli is the least costly approach to maximize treatment availability. Cost savings associated with native E. coli utilization may liberate funds for Erwinase procurement for patients with ASN hypersensitivity. Future analyses needed include an evaluation of costs associated with preventing abandonment due to compliance complexity with native E. coli given increased administration frequency compared with PEG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsparaginaseAntineoplastic AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansChildEscherichia coliForecastingPolyethylene Glycols

Substanzen

AsparaginaseAntineoplastic AgentsPolyethylene Glycols

Autor:innen und Institutionen

  • Emergency Medicine Residency at the Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA.
  • Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, NY.
  • Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
  • Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada.

ORCID-Profile: Terence M Hughes, Nitin Shrivastava, Lewis B Silverman, A Lindsay Frazier, Sumit Gupta, Avram Denburg

Zitieren

APA

Hughes, T. M., Shrivastava, N., Silverman, L. B., Frazier, A. L., Gupta, S., & Denburg, A. (2025). Forecasting Asparaginase Need and Cost for Childhood Cancer Using ACCESS FORxECAST. JCO Global Oncology. https://doi.org/10.1200/go-24-00444

Vancouver

Hughes TM, Shrivastava N, Silverman LB, Frazier AL, Gupta S, Denburg A. Forecasting Asparaginase Need and Cost for Childhood Cancer Using ACCESS FORxECAST. JCO Global Oncology. 2025. doi:10.1200/go-24-00444

BibTeX
@article{Hughes2025,
  author = {Hughes, Terence M and Shrivastava, Nitin and Silverman, Lewis B and Frazier, A Lindsay and Gupta, Sumit and Denburg, Avram},
  title = {Forecasting Asparaginase Need and Cost for Childhood Cancer Using ACCESS FORxECAST},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00444}
}
Kostenlos starten →